Should You Buy This US Penny Stock-OTLK

Acrobull Canada Advisory Inc.

November 26			2024
Name	Ticker	Sector/Industry		Market Cap	Risk Factor
Outlook Therapeutics, Inc.	OTLK-NASDAQ	Healthcare		$116.622 Million	High

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010.

Recent Highlights

Increase in Total Assets- The company’s total assets have increased in recent years, hence a positive momentum is expected to continue, it has reported total assets of $ 47,091,727 as compared to $ 32,300,601 in the previous corresponding quarter.

We expect the company to deliver short term results given bought at the right time.

Third Quarter 2024 Financial Highlights

Received European Union (EU) and United Kingdom (UK) Marketing Authorization for LYTENAVA for the treatment of wet AMD

NORSE EIGHT current enrollment pace supports topline readout target of Q4 CY2024

Resubmission of the ONS-5010 Biologics License Application (BLA) on track for Q1 CY2025

Outlook Therapeutics reported net income attributable to common stockholders of $44.4 million, or $1.91 per basic share, and net loss attributable to common stockholders of $0.89 per diluted share, compared to a net loss attributable to common stockholders of $20.7 million, or $1.61 per basic and diluted share, for the same period last year.

Stock Observation-The company has reported good earnings in the third quarter of 2024 and reported stable results. The RSI level for the stock is at 34 which shows close to oversold conditions. The customers looking for a short term stock may choose to invest in it.

Risk Involved- Financial performance of the company may have an impact on the company stock performance.

Considering all the factors and financials of the company Acrobull Canada Advisory Inc. maintains Customer Choose Buy for the stock.

Disclaimer- Though our research is fundamentally and technically based on Acrovest only provides general advice on the stocks and it is imperative for the investors to do the risk assessment for themselves before investing as Acrovest would not be liable for any loss or profit arising out through the investment made by the investors on our recommendations.

It is also advisable for the investors to consult with Financial Advisor, Broker or to seek any legal assistance as the research conducted by Acrobull Canada Advisory Inc. is factually based and recommendations are given in accordance with that, but it is imperative to understand that Acrobull Canada Advisory Inc. does not guarantee returns.

Acrobull Recommendation Based on Evaluation

Current Market Price	$4.93 USD
Acrobull Recommendation	Buy
Target Price	Target $5.66
RSI Level	14 Day RSI 33
Total Shares Outstanding	23.66 Million
Shares held by Insiders Risk Factor Stop Loss	35.88% High 5%